51. Impact of severe obesity in the management of patients with high-risk endometrial cancer: A FRANCOGYN study
- Author
-
Ombline Simon, Ludivine Dion, Krystel Nyangoh Timoh, Pierre François Dupré, Henri Azaïs, Sofiane Bendifallah, Cyril Touboul, Yohan Dabi, Olivier Graesslin, Emilie Raimond, Hélène Costaz, Yohan Kerbage, Cyrille Huchon, Camille Mimoun, Martin Koskas, Cherif Akladios, Lise Lecointre, Geoffroy Canlorbe, Pauline Chauvet, Lobna Ouldamer, Jean Levêque, Vincent Lavoué, CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, CHU Lille, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], CHU Strasbourg, CHU Pitié-Salpêtrière [AP-HP], CHU Clermont-Ferrand, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Oncogenesis, Stress, Signaling (OSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Jonchère, Laurent
- Subjects
MESH: Humans ,Clinical management ,MESH: Lymph Node Excision ,[SDV]Life Sciences [q-bio] ,Obstetrics and Gynecology ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics ,MESH: Obesity, Morbid ,Endometrial Neoplasms ,Obesity, Morbid ,[SDV] Life Sciences [q-bio] ,[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Endometrial cancer ,Reproductive Medicine ,Humans ,Lymph Node Excision ,MESH: Obesity ,Female ,Surgery ,Obesity ,MESH: Endometrial Neoplasms ,Neoplasm Recurrence, Local ,MESH: Female ,MESH: Neoplasm Recurrence, Local - Abstract
International audience; Objective: To assess the surgical management and survival of severely obese patients with high-risk endometrial cancer.Materials and methods: Data from 269 patients with high-risk endometrial cancer who were treated between 2001 and 2018 were collected from a multicenter database (11 centers). We classified the patients according to their BMI and compared outcomes in two groups: a normal weight group of women with a BMI < 25 kg/m2, and a severe obesity group of women with a BMI ≥ 35 kg/m2. The groups were compared for epidemiologic, pathologic, management, relapse-free survival (RFS) and overall survival (OS) elements.Results: Patients in the severe obesity group were younger (64 years vs. 68 years, p < 0.05) and had more comorbidities (hypertension, diabetes). They also had more locally advanced tumors and pelvic lymph node involvement (47% vs 24%, p < 0.05). The severely obese patients were less likely to undergo recommended surgical staging, with fewer lumbar aortic dissections than women of normal weight (23% vs 36%, p < 0.05) and fewer pelvic sentinel lymph node biopsies (26.5% vs 12.1%, p < 0.05). No difference in RFS or OS were observed between the two groups.Conclusion: Patients with severe obesity and high-risk endometrial cancer have more locally advanced tumors, and are less likely to be managed according to surgical recommendations. However, RFS and OS do not seem to be affected.
- Published
- 2022
- Full Text
- View/download PDF